吖啶橙对边缘性切除治疗软组织肉瘤患者的影响。
Impact of Acridine Orange in Patients With Soft Tissue Sarcoma Treated With Marginal Resection.
机构信息
Department of Orthopedic Surgery, Akita University Graduate School of Medicine, Akita, Japan
Department of Orthopedic Surgery, Sapporo Medical University School of Medicine, Sapporo, Japan.
出版信息
Anticancer Res. 2019 Nov;39(11):6365-6372. doi: 10.21873/anticanres.13849.
BACKGROUND/AIM: Although few studies have shown the effectiveness of adjuvant therapy with acridine orange (AO) for soft tissue sarcoma (STS) patients, no study has investigated this among cases with marginal resection. The aim of the study was to evaluate the effectiveness of AO therapy directly by comparing it to marginal resection cases that did not receive AO.
PATIENTS AND METHODS
This retrospective study included 19 and 33 patients with STS who received AO therapy (AO group) and marginal resection without AO therapy (non-AO group), respectively. The patients' clinical information was collected, and the clinical courses were compared.
RESULTS
The local recurrence rate in the AO group was significantly lower than that in the non-AO group (p<0.05). The local recurrence-free survival curves significantly differed between the two groups (p<0.05). High grade malignancy and no treatment with AO were identified as risk factors for local recurrence (p<0.05).
CONCLUSION
AO therapy strongly suppressed local recurrence after marginal resection of STS.
背景/目的：尽管少数研究表明吖啶橙（AO）辅助治疗软组织肉瘤（STS）患者的有效性，但尚无研究针对边缘性切除的病例进行调查。本研究旨在通过与未接受 AO 治疗的边缘性切除病例进行直接比较，来评估 AO 治疗的效果。
患者和方法
本回顾性研究纳入了分别接受 AO 治疗（AO 组）和边缘性切除且未接受 AO 治疗（非-AO 组）的 19 例和 33 例 STS 患者。收集患者的临床资料，并比较临床病程。
结果
AO 组的局部复发率明显低于非-AO 组（p<0.05）。两组的局部无复发生存曲线有显著差异（p<0.05）。高级别恶性肿瘤和未接受 AO 治疗是局部复发的危险因素（p<0.05）。
结论
AO 治疗强烈抑制了 STS 边缘性切除后的局部复发。
Zotero 插件